Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system

Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental neurology 2015-07, Vol.269, p.169-187
Hauptverfasser: Dyck, Scott M., Karimi-Abdolrezaee, Soheila
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 187
container_issue
container_start_page 169
container_title Experimental neurology
container_volume 269
creator Dyck, Scott M.
Karimi-Abdolrezaee, Soheila
description Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS. •CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.
doi_str_mv 10.1016/j.expneurol.2015.04.006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1698390244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001448861500120X</els_id><sourcerecordid>1698390244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</originalsourceid><addsrcrecordid>eNqFkEuP0zAURi0EYsrAXwAv2ST4lThhN6p4iZHYwNpy7JvWlWMH26nov8ejDrNldXWl893HQegdJS0ltP9wauHPGmBL0beM0K4loiWkf4Z2lIykYYKT52hHCBWNGIb-Br3K-UQIGQWTL9EN68badN0Ouf0xBpuiKy7gvPlZF8BrigXiwV-MDvkj_g4XvES7eV1iyriC5QjYwhl8XF04YB0sXnU5Rh8PzmADoSTtcYB0jlvG-ZILLK_Ri1n7DG8e6y369fnTz_3X5v7Hl2_7u_vGCC5LMwBwyzo-WMaZoZbJfpBSEj0by4QUY2cnSvsRJs7nQTDaaUqNmCcYqRkmyW_R--vc-sXvDXJRi8sGvNcB6jWqZgc-EiZEReUVNSnmnGBWa3KLThdFiXrwrE7qybN68KyIUNVzTb59XLJNC9in3D-xFbi7AlBfPTtIKhsHwYB1CUxRNrr_LvkLpsCVfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698390244</pqid></control><display><type>article</type><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</creator><creatorcontrib>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</creatorcontrib><description>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS. •CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2015.04.006</identifier><identifier>PMID: 25900055</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Axonal regeneration ; Brain Injuries - drug therapy ; Central ; Central Nervous System - drug effects ; Central Nervous System - metabolism ; Chondroitin sulfate proteoglycans ; Chondroitin Sulfate Proteoglycans - metabolism ; Chondroitin Sulfate Proteoglycans - pharmacology ; Development ; Extracellular matrix ; Glial scar ; Humans ; Intacellular mechanisms ; LAR ; Multiple sclerosis ; Nerve Regeneration - drug effects ; Nerve Regeneration - physiology ; Nervous system ; Neuronal Plasticity - drug effects ; Plasticity ; PTPσ ; Spinal Cord Injuries - drug therapy ; Spinal cord injury</subject><ispartof>Experimental neurology, 2015-07, Vol.269, p.169-187</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</citedby><cites>FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.expneurol.2015.04.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25900055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dyck, Scott M.</creatorcontrib><creatorcontrib>Karimi-Abdolrezaee, Soheila</creatorcontrib><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS. •CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</description><subject>Animals</subject><subject>Axonal regeneration</subject><subject>Brain Injuries - drug therapy</subject><subject>Central</subject><subject>Central Nervous System - drug effects</subject><subject>Central Nervous System - metabolism</subject><subject>Chondroitin sulfate proteoglycans</subject><subject>Chondroitin Sulfate Proteoglycans - metabolism</subject><subject>Chondroitin Sulfate Proteoglycans - pharmacology</subject><subject>Development</subject><subject>Extracellular matrix</subject><subject>Glial scar</subject><subject>Humans</subject><subject>Intacellular mechanisms</subject><subject>LAR</subject><subject>Multiple sclerosis</subject><subject>Nerve Regeneration - drug effects</subject><subject>Nerve Regeneration - physiology</subject><subject>Nervous system</subject><subject>Neuronal Plasticity - drug effects</subject><subject>Plasticity</subject><subject>PTPσ</subject><subject>Spinal Cord Injuries - drug therapy</subject><subject>Spinal cord injury</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuP0zAURi0EYsrAXwAv2ST4lThhN6p4iZHYwNpy7JvWlWMH26nov8ejDrNldXWl893HQegdJS0ltP9wauHPGmBL0beM0K4loiWkf4Z2lIykYYKT52hHCBWNGIb-Br3K-UQIGQWTL9EN68badN0Ouf0xBpuiKy7gvPlZF8BrigXiwV-MDvkj_g4XvES7eV1iyriC5QjYwhl8XF04YB0sXnU5Rh8PzmADoSTtcYB0jlvG-ZILLK_Ri1n7DG8e6y369fnTz_3X5v7Hl2_7u_vGCC5LMwBwyzo-WMaZoZbJfpBSEj0by4QUY2cnSvsRJs7nQTDaaUqNmCcYqRkmyW_R--vc-sXvDXJRi8sGvNcB6jWqZgc-EiZEReUVNSnmnGBWa3KLThdFiXrwrE7qybN68KyIUNVzTb59XLJNC9in3D-xFbi7AlBfPTtIKhsHwYB1CUxRNrr_LvkLpsCVfg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Dyck, Scott M.</creator><creator>Karimi-Abdolrezaee, Soheila</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</title><author>Dyck, Scott M. ; Karimi-Abdolrezaee, Soheila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-8ee3d2538d232c1d27687770afcd247495db1169eb33f84215a11c4fbe91c8b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Axonal regeneration</topic><topic>Brain Injuries - drug therapy</topic><topic>Central</topic><topic>Central Nervous System - drug effects</topic><topic>Central Nervous System - metabolism</topic><topic>Chondroitin sulfate proteoglycans</topic><topic>Chondroitin Sulfate Proteoglycans - metabolism</topic><topic>Chondroitin Sulfate Proteoglycans - pharmacology</topic><topic>Development</topic><topic>Extracellular matrix</topic><topic>Glial scar</topic><topic>Humans</topic><topic>Intacellular mechanisms</topic><topic>LAR</topic><topic>Multiple sclerosis</topic><topic>Nerve Regeneration - drug effects</topic><topic>Nerve Regeneration - physiology</topic><topic>Nervous system</topic><topic>Neuronal Plasticity - drug effects</topic><topic>Plasticity</topic><topic>PTPσ</topic><topic>Spinal Cord Injuries - drug therapy</topic><topic>Spinal cord injury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dyck, Scott M.</creatorcontrib><creatorcontrib>Karimi-Abdolrezaee, Soheila</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dyck, Scott M.</au><au>Karimi-Abdolrezaee, Soheila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2015-07</date><risdate>2015</risdate><volume>269</volume><spage>169</spage><epage>187</epage><pages>169-187</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><abstract>Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS. •CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25900055</pmid><doi>10.1016/j.expneurol.2015.04.006</doi><tpages>19</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-4886
ispartof Experimental neurology, 2015-07, Vol.269, p.169-187
issn 0014-4886
1090-2430
language eng
recordid cdi_proquest_miscellaneous_1698390244
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Axonal regeneration
Brain Injuries - drug therapy
Central
Central Nervous System - drug effects
Central Nervous System - metabolism
Chondroitin sulfate proteoglycans
Chondroitin Sulfate Proteoglycans - metabolism
Chondroitin Sulfate Proteoglycans - pharmacology
Development
Extracellular matrix
Glial scar
Humans
Intacellular mechanisms
LAR
Multiple sclerosis
Nerve Regeneration - drug effects
Nerve Regeneration - physiology
Nervous system
Neuronal Plasticity - drug effects
Plasticity
PTPσ
Spinal Cord Injuries - drug therapy
Spinal cord injury
title Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chondroitin%20sulfate%20proteoglycans:%20Key%20modulators%20in%20the%20developing%20and%20pathologic%20central%20nervous%20system&rft.jtitle=Experimental%20neurology&rft.au=Dyck,%20Scott%20M.&rft.date=2015-07&rft.volume=269&rft.spage=169&rft.epage=187&rft.pages=169-187&rft.issn=0014-4886&rft.eissn=1090-2430&rft_id=info:doi/10.1016/j.expneurol.2015.04.006&rft_dat=%3Cproquest_cross%3E1698390244%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698390244&rft_id=info:pmid/25900055&rft_els_id=S001448861500120X&rfr_iscdi=true